(Q34531880)

2 August 2017

1 reference

title

Anti-CGRP monoclonal antibodies in migraine: current perspectives (English)

1 reference

2 August 2017

1 reference

1 reference

1 reference

Paolo Martelletti

6

0 references

Martina Curto

object named as

Martina Curto

3

0 references

Andrea Negro

object named as

Andrea Negro

4

0 references

author name string

Maria Adele Giamberardino

1

1 reference

PubMed ID

27339365

2 August 2017

Giannapia Affaitati

2

1 reference

PubMed ID

27339365

2 August 2017

Raffaele Costantini

5

1 reference

2 August 2017

23 June 2016

1 reference

Internal and emergency medicine

2 August 2017

1 reference

2 August 2017

11

1 reference

2 August 2017

1045-1057

1 reference

2 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1007/s11739-016-1489-4

2 August 2017

0 references

cites work

A case of typical headache with an atypical diagnosis.

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Headache disorders are third cause of disability worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Emerging drugs for migraine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

New therapeutic approaches for the prevention and treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

The Journey to Establish CGRP as a Migraine Target: A Retrospective View.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Calcitonin gene-related peptide and migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Calcitonin gene-related peptide (CGRP): a new target for migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

The therapeutic potential of novel anti-migraine acute therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Emerging treatments for the primary headache disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Targeting CGRP: A New Era for Migraine Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Therapeutic antibodies against CGRP or its receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

CGRP receptor antagonism and migraine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

CGRP receptor antagonists: an expanding drug class for acute migraine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Emerging target-based paradigms to prevent and treat migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Epidemiological classification and social impact of chronic headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Chronic migraine: comorbidities, risk factors, and rehabilitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Chronic headaches and medication overuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Update on Medication-Overuse Headache and Its Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Triptan therapy in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

NSAIDs and cardiovascular disease: time to say no to diclofenac.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Effects of treatment of peripheral pain generators in fibromyalgia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Myofascial pain syndromes and their evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Effects of treatment of myofascial trigger points on the pain of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Impact of migraine on fibromyalgia symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Viscero-visceral hyperalgesia: characterization in different clinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Contribution of myofascial trigger points to migraine symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Pain thresholds in women with chronic pelvic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Correlation between Migraine Severity and Cholesterol Levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

The Use of Antiepileptics in Migraine Prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

The vascular theory of migraine--a great story wrecked by the facts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Migraine pathophysiology and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Calcitonin gene-related peptide (CGRP) and migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Migraine: where and how does the pain originate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Recent advances in understanding migraine mechanisms, molecules and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Diencephalic and brainstem mechanisms in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Distribution and chromatographic characterisation of CGRP-like immunoreactivity in the brain and gut of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Calcitonin gene-related peptide: physiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

21 January 2018

RAMPs and CGRP receptors

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Calcitonin receptor-like receptor and receptor activity modifying protein 1 in the rat dorsal horn: localization in glutamatergic presynaptic terminals containing opioids and adrenergic alpha2C receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

The role of peptides in central sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Evidence for a vascular factor in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

CGRP may play a causative role in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Sensitization of meningeal sensory neurons and the origin of headaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Isolation of Potent CGRP Neutralizing Antibodies Using Four Simple Assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

ICHD-3 beta is published. Use it immediately

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1489-4

Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP

21 January 2018

1 reference

12 December 2020

Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain

1 reference

12 December 2020

New players in the preventive treatment of migraine

1 reference

12 December 2020

CGRP antibodies: the Holy Grail for migraine prevention?

1 reference

12 December 2020

The therapeutic armamentarium in migraine is quite elderly

1 reference

12 December 2020

Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally

1 reference

12 December 2020

Neurokinin-1 receptor agonists are involved in mediating neutrophil accumulation in the inflamed, but not normal, cutaneous microvasculature: an in vivo study using neurokinin-1 receptor knockout mice

1 reference

12 December 2020

Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats

1 reference

12 December 2020

The International Classification of Headache Disorders, 3rd edition (beta version)

1 reference

12 December 2020

Isolation, purification and characterization of beta-hCGRP from human spinal cord

1 reference

12 December 2020

Chapter 24 Referred pain from internal organs

1 reference

12 December 2020

Site of effect of LY2951742 for migraine prophylaxis

1 reference

12 December 2020

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

1 reference

12 December 2020

10.1007/S11739-016-1489-4

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

27339365